METHOD OF TREATING DEFECTS OF SKIN AND SOFT TISSUES IN PATIENTS WITH DIABETES MELLITUS AND METHOD OF INTRODUCTION OF DRUG THEREFOR Russian patent published in 2019 - IPC A61K35/16 A61P17/02 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to surgery, and can be used to treat skin and soft tissue defects in patients with diabetic foot syndrome. Method of treatment includes wound cleansing, application and implantation of wound-healing material and closing the wound surface, characterized in that wound cleansing is performed by ultrasonic hydrosurgical treatment with simultaneous jet irrigation and irrigation with an anesthetic solution, after cleansing and stopping the swelling of the paravulnar tissues, an introduction to the autoplasma of platelet-rich autoplasma is carried out in the paravulnar tissue and in the tissue of the wound defect, then an application is made on the wound surface of the G-derm matrix-plastic biomaterial; the wound surface is closed by applying interactive dressings: hydrocolloid or hydrogel to create a moist physiological environment, with the transition to 5–7 days atraumatic dressings. Method of administration of platelet-rich autoplasma (PlRAp) involves the introduction into the paravulnar tissues and the area of the bottom and walls of the wound defect as follows: tissue is punctured into the entire required depth with an injection needle for intramuscular injection of drugs, while the needle cut is oriented in the direction of the surface tissue. Next, a tissue tunnel is formed, and then at the needle exit, being slowly pulled toward person, PlRAp is smoothly injected into the tissue tunnel until the filled tunnel is completely filled and spread through the tunnel into the tissue mass, the injection is performed evenly over the entire surface, focusing on infiltrating the PlRAp tissues.

EFFECT: use of inventions allows to treat skin and soft tissue defects by stimulating secondary angiogenesis and the processes of regeneration of body tissues, eliminate shortcomings in the complex of growth factors and ensuring their synergistic action, eliminating the risk of infection transmission and the occurrence of allergic reactions, stimulating effective histo-and organ-specific reparation, creating optimal conditions for primary adhesion, migration and proliferation of allo- and autocell, optimizing metabolic processes and stimulating a positive course of the wound process in patients with diabetes and creating the maximum concentration of growth factors in the tissues.

2 cl, 16 dwg, 3 ex